Charlesson received two SBIR grants from the NIH totaling close to $1.6 million to support development of a nanoparticle-formulated therapy for eye disease and a preclinical genetic animal model for age-related macular degeneration (AMD).
Specifically, the firm obtained $210,357 to validate and commercialize its mouse model of AMD. Charlesson also received over $1.38 million in a phase 2 SBIR grant to develop CLT-004 for treating AMD, diabetic retinopathy, and diabetic macular edema. These funds will be used to develop IND-enabling efficacy, safety, and toxicity profiles.
CLT-004 is a small molecule that reduces retinal inflammation and vascular leakage, according to Charlesson. The firm is developing a sustained-release nanoparticle formulation of CLT-004 to treat blinding retinal disease.